Prostate biopsy and prostate cancer management in patients with haemophilia: The experience of French Haemophilia Treatment Centres
| العنوان: | Prostate biopsy and prostate cancer management in patients with haemophilia: The experience of French Haemophilia Treatment Centres |
|---|---|
| المؤلفون: | Philippe Gautier, Benoit Guillet, Marianne Sigaud, Ségolène Claeyssens, Fabienne Genre Volot, Pierre Chamouni, Anne Lienahrt, Birgit Frotscher, Alexandra Fournel, Sabine Castet, Catherine Poumayou, Valérie Gay, Rodolphe Thuret, Bénédicte Wibaut, Christine Biron‐Andreani |
| المصدر: | Haemophilia. 28:437-444 |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Male, Biopsy, Prostate, Prostatic Neoplasms, Hemorrhage, Hematology, General Medicine, Middle Aged, Hemophilia A, Humans, Deamino Arginine Vasopressin, Genetics (clinical), Aged, Hematuria, Retrospective Studies |
| الوصف: | Data are limited on prostate cancer (PC) management in patients with haemophilia (PWH).To describe PC screening and diagnosis, treatment modalities and bleeding complications in a group of unselected PWH followed at French Haemophilia Treatment Centres (HTCs) PATIENTS AND METHODS: PC screening, management and bleeding complications were retrospectively investigated at 14 French HTCs between 2003 and 2018.Among1549 50-year-old PWHs, 73 (4.7%) underwent PC screening (median age 71.1 years; 67/6 HA/HB, 17/56 severe-moderate/mild). At diagnosis, haematuria was infrequent. Prophylaxis was administered during 76/86 (88%) prostate biopsies (PB) (n = 67 clotting factor concentrates, CFC; n = 9 desmopressin; n = 17 associated with tranexamic acid, TA). Bleeding (11/86, 12.8%) occurred mainly post-prophylaxis (median delay: 7 days): haematuria (9/11, 81.8%), and rectal bleeding (2/11, 18.2%) including one major (1.2%). PC was confirmed in 50/86 PB and in two prostatectomy specimens (total n = 50 patients, n = 6 with only active surveillance). Surgery (n = 28/44 patients) was managed with CFC. Fifteen patients had radiotherapy/brachytherapy, 10 had hormone therapy; CFC-based prophylaxis was only prescribed for brachytherapy (n = 2). Major bleedings occurred in 3/28 (10.7%) and 2/15 (13.3%) patients who underwent surgery and radio/brachytherapy, respectively. No bleeding risk factor was found.Our data indicate that PB requires prophylaxis for atleast 7 days, using CFC, desmopressin or TA in function of haemophilia severity. PC surgery should be considered at high bleeding risk. Long-term post-procedural CFC or oral TA could be discussed. Radiotherapy/brachytherapy also should be managed with prophylaxis (CFC or TA). |
| تدمد: | 1365-2516 1351-8216 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9709f5ed31a98eebeca8734b030f9757 https://doi.org/10.1111/hae.14507 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....9709f5ed31a98eebeca8734b030f9757 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13652516 13518216 |
|---|